Merck, SpringWorks

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks
Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics. Merck, in a statement, said its negotiations to buy SpringWorks are ongoing,
Germany’s Merck in Talks to Buy SpringWorks Therapeutics
Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
UPDATED: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker has attracted the attention of a biopharma bigwig from overseas. | Merck KGaA is in advanced talks to acquire cancer and rare disease specialist SpringWorks,
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring.
Merck In Talks to Buy Cancer Drugmaker Springworks
After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.
Merck KGaA confirms ‘advanced’ talks to acquire SpringWorks
Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms
SpringWorks Therapeutics jumps on report of Merck KGaA takeover talks
SpringWorks Therapeutics (NASDAQ:SWTX) soared 12% after a report that Merck KGaA (OTCPK:MKGAF) is in advanced discussions to acquire the cancer and rare disease drugmaker. If an agreement is reached,
Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.
EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition
Merck KGaA (“Merck”) reacts to press reports and confirms advanced discussions with Springworks Therapeutics, Inc. Merck also confirms that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize.
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year and hit a new 52-week high earlier in the session.
pharmaphorum2h
Merck confirms its interest in buying SpringWorks
Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...
Merck KGaA verhandelt Milliardendeal mit US-Tumorspezialisten
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
Better High-Yield Dividend Stock: Pfizer vs. Merck
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
An Investigation Has Commenced on Behalf of Merck & Co., Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MRK Losses.
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...
https//insights.som.yale.edu19h
What Investors Are Missing about Pfizer and Merck
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Devdiscourse14h
Merck's Ambitious Pursuit of SpringWorks: A Strategic Bet in Oncology
Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...
Merck downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...